cinnamic acid bornyl ester | 5033-96-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: cinnamic acid bornyl ester
• 英文别名: Zimtsaeure-bornylester；Cinnamic acid, 2-bornyl ester, endo-；(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl) (E)-3-phenylprop-2-enoate
• CAS: 5033-96-5；6330-67-2；41755-67-3；77942-64-4；96766-47-1
• 化学式: C₁₉H₂₄O₂
• 分子量: 284.398
• InChiKey: ACTRLDZRLKIJEH-MDZDMXLPSA-N

物化性质

• LogP：
  5.698 (est)
• 保留指数：
  2222.7

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (+)-冰片 、 肉桂酸 在 盐酸 作用下， 生成 cinnamic acid bornyl ester
  参考文献：
  名称：

  Hilditch, Journal of the Chemical Society, 1908, vol. 93, p. 7

  摘要：

  DOI：

文献信息

• Kava derived therapeutic compounds and methods of use thereof
  申请人：KUALITY HERBCEUTICS LLC

  公开号：US10624943B2

  公开（公告）日：2020-04-21

  Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.

  本发明的某些实施方案提供了一种组合物，该组合物包含至少两种选自由二氢麦角苷、甲基麦角苷、二氢卡瓦胡椒素、卡瓦胡椒素、去甲氧基麦角苷和11-甲氧基麦角苷组成的组的化合物，其中该组合物基本上不含黄卡瓦胡椒素B、向哺乳动物施用载体和选自由二氢甲基芪烷素、甲基芪烷素、二氢卡瓦胡椒素、卡瓦胡椒素、去甲氧基卡瓦胡椒素和 11-甲氧基卡瓦胡椒素组成的组的化合物，其中该化合物基本上不含其他卡瓦提取物成分。
• STRAHLUNGSHÄRTBARE LACKE
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0869998B1

  公开（公告）日：2002-05-08
• JPH09124474A
  申请人：——

  公开号：JPH09124474A

  公开（公告）日：1997-05-13
• KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：XING Chengguo

  公开号：US20160279184A1

  公开（公告）日：2016-09-29

  Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
• US6106905A
  申请人：——

  公开号：US6106905A

  公开（公告）日：2000-08-22